Monopar Therapeutics

MNPR

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

RA Capital Management Driehaus Capital Deerfield Management

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management9.9%Feb 17, 2026

SC 13G/ARA Capital Management9.9%Nov 14, 2025

SC 13G/A

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 667,207Value: $43.6M

# Signal Note: RA Capital Initiates $43.6M Position in Monopar Therapeutics RA Capital's entry into MNPR signals conviction in the company's lead program, Validive (clonidine mucoadhesive oral film), currently in Phase 3 for radiation-induced xerostomia (RIX) in head-and-neck cancer patients—a supportive care indication with limited approved options. The $43.6M stake (667K shares) represents a material commitment from a skilled crossover investor, suggesting upcoming near-term catalysts likely include Phase 3 readouts and potential accelerated regulatory pathways given unmet need and prior breakthrough therapy designation.

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SION3 funds NUVL3 funds INSP3 funds EWTX3 funds SYRE3 funds PRAX3 funds PTN2 funds TNDM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Driehaus Capital Initiates MNPR Position Driehaus's $2.2M entry into Monopar signals conviction in the company's clinical pipeline, likely driven by upcoming catalysts around its lead program Validive (rexinercept) for severe oral mucositis in cancer patients—a high-burden, underserved indication with Phase 2b data expected in 2024-2025. The growth-focused fund's initiation suggests confidence in either trial readout probability or commercial potential, though MNPR's market cap under $100M carries execution risk typical of early-stage biotech.